Systems medicine
Biography 
Dr. Haitao Lyu is an associate professor with tenure at School of Chinese Medicine, and a principal investigator at Institute for Research and Continuing Education in Hong Kong Baptist University, an elected fellow of The Royal Society of Chemistry, an elected fellow of The Royal Society of Biology, and an invited Faculty Member in Faculty Opinions (Faculty 1000 Prime). Between 2013 and 2023, Dr. Lyu was ever a professor with tenure at Shanghai Center for Systems Biology in Shanghai Jiao Tong University, a professor/assistant dean at School of Pharmaceutical Sciences in Chongqing University. Prior to undertake a postdoctoral training in Albert Einstein College of Medicine, Washington University School of Medicine, MIT SMART Center from 2009 to 2013, Dr. Lyu obtained bachelor’s degree in Chinese Materia Medica in 2004 and PhD degree in Pharmacognosy in 2009 from School of Pharmaceutical Sciences in Heilongjiang University of Chinese Medicine. Dr. Lyu’s group mostly concentrates on next-generation functional metabolomics for the interdisciplinary innovations of life and health sciences, and Dr. Lyu has secured more than 10 competitive grants from different funding agencies, such as National Natural Science Foundation of China, Ministry of Science and Technology of People’s Republic of China, Shanghai Bureau of Science and Technology of China, Agilent Technologies, etc. Dr. Lyu has published 58 authored and co-authored articles in many high profile journals. Dr. Lyu resumes the role of Editorial Board of many prestigious journals, including Pharmacological Research (Q1 TOP, IF 10.3, Section Editor), Phytomedicine (Q1 TOP, IF 6.5, Former Associate Editor), Royal Society Open Sciences (Q1, IF 3.6, Associate Editor), Proteomics (Q1, IF 5.3, EBM), and Acta Pharmaceutica Sinica B (Q1 Top, IF 14.3, EBM). Dr. Lyu is recipient of QUT Vice Chancellor Research Fellowship (2013), recipient of Agilent ACT-UR Award (2021), recipient of Faculty Opinions Member of The Year Award (2022), and recipient of Editorial Board Member of Excellence for Acta Pharmaceutica Sinica B (2022).
Research Interests
- Functional Metabolomics
- Precision Oncology
- Microbial Metabolism
- Systems Pharmacology
Selected Publications
1. Liu, J., Jing, Wang., Wang, T., Hu, Z., and Lu, H*. (2023). Functional metabolomics revealed the dual-activation of cAMP-AMP axis is a novel therapeutic target of pancreatic cancer. Pharmacological Research, 187, 106554 (*Corresponding Author) (Q1 TOP, IF 10.3)
2. Wang, T., Hu, L., …..Liu, J., Xia, H. and Lu, H*. (2022). Functional metabolomics defined metabolic-characteristics of chronic hepatitis that is significantly differentiated from acute hepatitis. Pharmacological Research, 180, 106248 (*Corresponding Author) (Q1 TOP, IF 10.3)
3. Luo，H., Cao, G., ... Lu, H*., Wang, Y*. and Jing, W*., etc.,(2022). Emerging pharmacotherapy for inflammatory bowel diseases. Pharmacological Research,178, 106146. (*Corresponding Author) (Q1 TOP, IF 10.3)
4. Dong, S., Zhu, M.,...Hu, L., Jing, W*., Lu, H*. and Wang, S., etc (2021). Dihydromyricetin improves DSS-induced colitis in mice via modulation of fecal-bacteria-related bile acid metabolism. Pharmacological Research, 171, 105767. (*Corresponding Author) (Q1 TOP, IF 10.3)
5. Wang, T., Liu, J., Luo, X., Hu, L., and Lu, H*. (2021). Functional metabolomics innovates therapeutic discovery of traditional Chinese medicine derived functional compounds. Pharmacology & Therapeutics, 224, 107824. (*Corresponding Author). (Q1 TOP, IF 13.4)
6. Jing, W., Luo, X., and Lu, H*., et al. (2021). Berberine improved the colitis in rats by the regulation of microbial tryptophan metabolites to activate AhR. Pharmacological Research, 164, 105358. (*Corresponding Author) (Q1 TOP, IF 10.3)
7. Guo, R., Luo, X., Liu, J., and Lu, H*. (2021). Mass spectrometry based targeted metabolomics precisely characterized new functional metabolites that regulate biofilm formation in Escherichia coli. Analytica Chimica Acta, 1145, 26-36. (*Corresponding Author) (Q1 TOP, IF 6.9)
8. Liu, J., Luo, X., Guo, R. and Lu, H*. (2020). Cell metabolomics reveals berberine inhibited cell viability and metastasis in pancreatic cancer cells by regulating citrate metabolism. Journal of Proteome Research, 19: 3825-3836 (*Corresponding Author) (Q1, IF 5.37)
9. Luo, X., Liu, J., Lu, H*., etc. (2020). Metabolomics identified new biomarkers for the precise diagnosis of pancreatic cancer and associated tissue metastasis. Pharmacological Research, 156, 104805. (*Corresponding Author) (Q1 TOP, IF 10.3)
10. Guo, R., Luo, X., Liu, J., Lu, H*., etc. (2020). Multi-omics strategies decipher therapeutic discovery of traditional Chinese medicine. Pharmacological Research, 19, 3825–3836. (*Corresponding Author) (Q1 TOP, IF 10.3)